Stem Cell News

BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.

As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.

Ncardia launches Ncyte® Microglia

February 4, 2025 By BioInformant Team Leave a Comment

LEIDEN, THE NETHERLANDS, February 4, 2025 — Ncardia, a global leader in human induced pluripotent stem cell (hiPSC) technology, today announced the launch of Ncyte^® Microglia, a groundbreaking tool to advance research in neurodegenerative diseases and central nervous system (CNS) disorders.

Ncyte^® Microglia are hiPSC-derived models that closely mimic primary human microglia, exhibiting key functional characteristics such as phagocytosis, cytokine signaling response, and the expression of microglial markers including IBA1, TREM2, and TMEM119. These features make Ncyte^® Microglia highly suitable for studying microglial behavior in disease-relevant contexts, assessing immune responses, and enabling high-throughput drug screening applications. [Read more…]

Innovative Functional Peptides Successfully Co-Developed as Alternatives to Growth Factors Used in the Manufacturing of Regenerative Medicine Products

January 29, 2025 By Cade Hildreth, Founder & President Leave a Comment

Orizuru Therapeutics, Inc. (OZTx), a Japanese biotechnology company focusing on the research and development of iPSC-derived regenerative medicine, and PeptiGrowth Inc. (PeptiGrowth), a Japanese biotechnology company specializing in the development of synthetic peptide based growth factors, are pleased to announce the successful completion of the joint development project (first announced on August 23, 2023) for chemically synthesized peptide as an alternative to specific recombinant growth factors used in the manufacturing of regenerative medicine products developed by OZTx. The developed peptide was confirmed to bind to cellular receptors in a manner similar to the respective recombinant growth factor, inducing phosphorylation and signaling within the cells, thereby triggering differentiation and proliferation of iPSCs. [Read more…]

Eterna Therapeutics Releases Positive Preclinical Results for ERNA-101, an Allogenic iMSC Therapeutic

January 18, 2025 By Cade Hildreth, Founder & President Leave a Comment

ERNA-101 is a cell therapy that utilizes iPSCs to create induced allogenic mesenchymal stem cells (iMSCs) that secrete interleukins IL-7 and IL-15.

Proof-of-concept study provides roadmap for treatment of ovarian cancer.

CAMBRIDGE, Mass., Jan. 14, 2025 — Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, announced positive results from a preclinical study on the company’s lead cell therapy product, ERNA-101, which is designed to activate and regulate the immune system’s response to recognize and attack ovarian cancer cells. This successful proof-of-concept study demonstrated massive T cell infiltration after only one dose of ERNA-101, reduced tumor burden, and extended survival in mice with ovarian cancer. [Read more…]

IPS HEART’s Secures Orphan Drug Designation for iPSC-Derived Mesenchymal Progenitor Cell (MPC) Therapy, GIVI-MPC

January 18, 2025 By Cade Hildreth, Founder & President Leave a Comment

In a groundbreaking development for the treatment of muscular dystrophies, IPS HEART received Orphan Drug Designation (ODD) from the U.S. FDA on January 13th, 2025, for its innovative stem cell therapy, GIVI-MPCs. GIVI-MPCs are mesenchymal progenitor cells derived from induced pluripotent stem cells (iPSCs) that have the potential to treat Becker Muscular Dystrophy (BMD). This milestone recognizes the therapy’s unprecedented ability to generate new skeletal muscle containing full-length dystrophin—a crucial protein missing or defective in individuals with BMD. [Read more…]

CHU Toulouse receives CTA Approval to initiate ALLOFIST, a Phase 1/2 Trial based on Cell-Easy’s proprietary adipose-derived MSC in Patients suffering from Crohn Disease.

January 16, 2025 By Cade Hildreth, Founder & President Leave a Comment

Toulouse, France, January 16, 2025 – The long-term partnership between Cell-Easy and Toulouse University Hospital (CHU Toulouse) continues to bear fruits, bringing innovative MSC-based therapies to local patient cohorts. This time, it’s in the field of Crohn’s disease that the pair is experimenting with the allogeneic cell therapy approach. By tackling all CMC, regulatory and medico-economic concerns, the Cell-Easy CDMO has succeeded in developing a cell therapy drug from scratch in just 2 years. The principal investigator Dr Etienne Buscail, a colo-rectal surgeon and proctologist at Toulouse University Hospital, recently submitted a request for authorization of CTA to the European Agency EMA, which was rapidly accepted. An initial cohort of patients suffering from Crohn’s disease will be able to benefit from this experimental innovant treatment starting in 2025 Q1. [Read more…]